Table 2 Adjusted Odds Ratio for Risk of ACS According to Five Selected Plasma Cytokines in Two Case-control Validation Sets.

From: A multi-stage association study of plasma cytokines identifies osteopontin as a biomarker for acute coronary syndrome risk and severity

Cytokines

Validation Set 1

Validation Set 2

Pooled analysis of the two validation sets

Adjusted OR (95% CI)

P

Adjusted OR (95% CI)

P

Adjusted OR (95% CI)

P

Osteopontin

  Model 1

4.65 (2.49–8.67)

<0.001

3.86 (2.39–6.22)

<0.001

4.12 (2.81–6.04)

<0.001

  Model 2

4.68 (2.48–8.85)

<0.001

3.64 (2.24–5.90)

<0.001

4.04 (2.74–5.95)

<0.001

  Model 3

3.89 (1.56–5.47)

0.023

5.98 (3.43–10.44)

<0.001

4.64 (3.16–6.79)

<0.001

CCL23

  Model 1

2.57 (1.57–4.22)

<0.001

9.64 (4.46–20.83)

<0.001

4.70 (1.38–15.97)

0.013

  Model 2

2.54 (1.55–4.17)

<0.001

8.80 (4.12–18.81)

<0.001

4.11 (2.76–6.10)

0.009

  Model 3

3.01 (1.51–5.99)

0.002

4.37 (2.56–7.46)

<0.001

3.60 (2.45–5.28)

<0.001

BDNF

  Model 1

0.53 (0.41–0.69)

<0.001

0.55 (0.41–0.74)

<0.001

0.54 (0.44–0.66)

<0.001

  Model 2

0.51 (0.39–0.67)

<0.001

0.56 (0.42–0.75)

<0.001

0.54 (0.44–0.66)

<0.001

  Model 3

0.66 (0.49–0.90)

0.009

0.60 (0.39–0.91)

0.015

0.66 (0.49–0.90)

<0.001

MSP

  Model 1

1.58 (1.08–2.33)

0.019

1.17 (0.82–1.52)

0.484

1.28 (1.01–1.61)

0.039

  Model 2

1.54 (1.04–2.27)

0.031

1.18 (0.86–1.62)

0.315

1.29 (1.02–1.63)

0.034

  Model 3

2.02 (0.81–5.06)

0.132

1.20 (0.76–1.89)

0.434

1.33 (0.92–1.91)

0.130

CRP

  Model 1

2.56 (1.95–3.38)

<0.001

5.08 (3.27–7.89)

<0.001

3.29 (2.60–4.17)

<0.001

  Model 2

2.56 (1.94–3.39)

<0.001

5.17 (3.28–8.14)

<0.001

3.29 (2.60–4.18)

<0.001

  Model 3

2.54 (1.39–4.66)

0.003

3.08 (1.87–5.09)

<0.001

2.67 (1.88–3.79)

<0.001

  1. Plasma cytokine levels were ln-transformed prior to analysis, and the ORs were shown as per SD increase of the ln-transformed value of each cytokines. Model 1: Adjusted for age (continuous). Model 2: Additionally, adjusted for BMI (continuous) and smoking status (current, former and never). Model 3: Additionally adjusted for total cholesterol (continuous), low-density lipoprotein cholesterol (continuous), triglycerides (continuous), fasting glucose (continuous), estimated glomerular filtration rate (continuous), systolic blood pressure (continuous), systolic blood pressure (continuous), anti-hypertensive medication (binary), and lipid-lowing medication (binary).
Back to article page